Skip to main content
OpenTrials
Completed

NCT Number: NCT02332330

CD0104 VEST II Post Marketing Surveillance Study

This study is designed to collect post market data on use of the VEST, particularly on saphenous vein grafts to the right territory of the heart.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Krankenhaus der Barmherzigen Bruder, Trier, Germany

Loading trial locations.

About this study

The primary objective is to test the early-mid term patency rate of VEST supported Right Coronary Artery (RCA) bypass grafts. The research participants will undergo CABG preparations and CABG procedure routinely as is the standard of care. During the procedure the VEST will be implanted on the vein graft to the Right Coronary Artery according to the IFU. Perioperative care is according to standard of care. Upon discharge patient will be prescribed statins and aspirin for 6 months. Patient will attend a routine clinic visit 4-6 weeks post operatively. The last study visit will occur 3-6 months post operatively. Patients will undergo a noninvasive coronary CT angiography.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient scheduled for on-pump CABG on clinical grounds
  • At least one vein graft bypass indicated for right coronary artery and LIMA indicated for the LAD on clinical grounds
  • Appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and adequate vascular bed, as assessed from the pre-operative cardiac angiography.

Exclusion criteria

  • Concomitant non-CABG cardiac procedure
  • Prior cardiac surgery
  • Emergency CABG surgery (cardiogenic shock, inotropic pressure support, IABP)
  • Contraindication for on-pump CABG with cardioplegic arrest (e.g. severely calcified aorta)
  • Calcification at the intended anastomotic sites, as assessed upon opening of the chest and before VEST implantation.
  • Prior debilitating stroke less than 1 year before surgery
  • Severe renal dysfunction (Cr>2.0 mg/dL)
  • Concomitant life-threatening disease likely to limit life expectancy to less than 2 years.

Treatment and study plan

VEST

Device

Primary outcomes

  1. Vein graft patency by CT angiography

    Time frame: 3-6 monthws

  2. MACCE

    Time frame: 3-6 months

    Major adverse cardiac and cerebral events

Sponsors and collaborators

Lead sponsor

Vascular Graft Solutions Ltd.

Industry

Registry information

Official study title

A Post-market Prospective Study of the VGS VEST (Venous External Support), Supporting Saphenous Vein Grafts for Coronary Bypass Graft Surgery in Patients With Severe Coronary Heart Disease

Acronym: VEST II

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jan 6, 2015
Registry last updated
Apr 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.